

Claims

1. A sorbefacient comprising hexylene glycol and 1-menthol.
2. The sorbefacient according to claim 1, wherein hexylene glycol is 1-10% by weight and 1-menthol is 0.1-7% by weight to the total amount of the preparation.
3. A base for a percutaneously absorbing preparation according to claim 1 or 2, wherein the ratio of hexylene glycol to 1-menthol is from 1:0.1 to 1:7.
4. The base for a percutaneously absorbing preparation according to claims 1 to 3, wherein styrene-isoprene-styrene block copolymer and/or polyisobutylene, softener and tackifier are essential components and hexylene glycol and 1-menthol are sorbefacients as the components of the base.
5. The base for a percutaneously absorbing preparation according to claims 2 to 4, wherein 10-40% by weight of styrene-isoprene-styrene block copolymer, 2-10% by weight of polyisobutylene, 10-60% by weight of softener and 20-60% by weight of tackifier are essential components and 1-10% by weight of hexylene glycol and 0.1-7% by weight of 1-menthol are compounded therewith as the components of the base.
6. A percutaneously absorbing preparation according to claims 4 to 5, wherein a pharmaceutical agent is contained as an effective ingredient.

7. The percutaneously absorbing preparation according to claims 4 to 6, wherein the pharmaceutical agent is follicular hormone and/or luteinizing hormone.

8. The percutaneously absorbing preparation according to claim 7, wherein the follicular hormone is estradiol or a derivative thereof and its compounding amount is 0.1-5% by weight.

9. The percutaneously absorbing preparation according to claim 7, wherein the luteinizing hormone is norethisterone, norethisterone acetate or a derivative thereof and its compounding amount is 0.5-10% by weight.